The many biological responses documented for lysophospholipids that include lysophosphatidic acid and sphingosine 1-phosphate can be mechanistically attributed to signaling through specific G protein-coupled receptors. At least nine receptors have now been identified, and the total number is likely to be larger. In this brief review, we note cogent features of lysophospholipid receptors, including the current nomenclature, signaling properties, development of agonists and antagonists, and physiological functions.
The increasingly well studied lysophospholipids (LPs) 1 known as lysophosphatidic acid or LPA (1) (2) (3) (4) (5) and sphingosine 1-phosphate or S1P (5, 6) ( Fig. 1) have garnered interest for their extracellular signaling properties. It is now clear that a majority of the responses documented for extracellular LPs is attributable to the activation of specific, seven-transmembrane domain G protein-coupled receptors (GPCRs). There are currently nine distinct LP receptors, four of which mediate effects of LPA and five that mediate effects of S1P (Table I ). These receptors have been known by many different orphan receptor names, which recently led to a consensus, receptor renaming, based upon the identity of high affinity ligands (7) : the LPA receptors consisting of LPA [1] [2] [3] [4] and S1P receptors consisting of S1P [1] [2] [3] [4] [5] (5, 8, 9) . Genetic nulls (Table II) have driven a number of recent analyses toward understanding physiological functions (see Fig. 3 ).
In addition to these proven receptors, an enlarging number of orphan receptors have been provisionally identified as LP receptors; however, in many cases conflicting data exist on their identity. In particular, some putative receptors for sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC) (10) may in fact be proton sensors, unrelated to LP signaling (11) ; these and other orphan/putative LP receptors are reviewed elsewhere (5) . Similarly, no attempt is made to cover the important developments in understanding LP biochemistry and metabolism, which have been the subject of many excellent reviews (3, 5, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . In this minireview, with apologies to many colleagues for citation limits, we highlight major features of LPA and S1P GPCRs.
LPA GPCRs
There are four identified LPA receptors in mammals (5) . A distinct gene encodes each receptor that activates downstream signaling pathways mediated by one or more G proteins (Tables I   and II; Figs. 2 and 3) . The first three, LPA [1] [2] [3] , share sequence homology with one another, whereas LPA 4 is divergent in sequence. LPA 1 represents the first LP receptor identified. In mice, a multi-exon gene structure was reported, with the coding region characterized by conservation of a single intron separating two coding regions at the sixth transmembrane domain. This intronic structure is shared with lpa 2 and lpa 3 . LPA 1 contains 364 amino acids (aa) in a seven-transmembrane receptor structure, with an apparent molecular mass of ϳ41 kDa. LPA 1 couples to multiple G proteins (Fig. 2) . In both humans and mouse, adult expression is widespread and includes most major tissues. However, within a single tissue, heterogeneity of cell types expressing lpa 1 also exists. Targeted deletion of lpa 1 revealed ϳ50% perinatal lethality in a mixed background strain (Table II) . Remaining survivors showed reduced body mass and head/facial deformity and increased cell death of Schwann cells. Postnatal lethality was in part related to suckling problems associated with olfactory defects, whereas exencephaly and frontal brain hemorrhage likely contributed to a small proportion of embryonic loss. LPA signaling was lost or vastly decreased in mouse embryonic fibroblasts (MEFs) and cerebral cortical neuroprogenitor cells. Independent deletion of LPA 1 in mice has been associated with behavioral changes reminiscent of psychiatric disorders (22) . Key roles in cell migration have been recently described (23) as well as surprising effects on the formation of the central nervous system (Fig. 3) (24) .
LPA 2 was the second LPA receptor identified. A mutant variant named EDG-4 is absent from wild-type genomes and is therefore not synonymous with LPA 2 . Gene structure analyses reveal the conserved intron in transmembrane domain 6. LPA 2 contains 351 aa (human) or 348 aa (mouse) with a predicted molecular mass of ϳ39 kDa. LPA 2 also couples with multiple forms of G proteins ( Fig.  2 ) and shows widespread adult tissue expression in humans and mouse. It has been detected in various cancer cell lines, and variants within the 3Ј-untranslated region exist. Targeted genetic nulls of lpa 2 do not have blatant phenotypes yet do show defects and/or loss of wild-type LPA signaling in MEFs (Table II) . Double mutants of lpa 1 (Ϫ/Ϫ) and lpa 2 (Ϫ/Ϫ) show MEF defects in most LPArelated signaling (e.g. AC inhibition, c-Jun N-terminal kinase and Akt activation, PLC activation, Ca 2ϩ mobilization, stress fiber formation, and cell proliferation). The dual elimination of both receptors has also revealed involvement in central nervous system development (24) .
LPA 3 also has a gene structure containing the conserved intron in transmembrane domain 6. It contains 353 aa (human) and 354 aa (mouse), with a predicted molecular mass of ϳ40 kDa. It differs from the other previous two LPA receptors by not coupling to G 12/13 ( Fig. 2) and showing a preference for LPA molecules with unsaturated acyl chains. Although still expressed in many adult tissues, it shows somewhat more restricted expression (5). Its signaling properties are generally similar to LPA 1 and LPA 2 except for ACrelated effects that vary with respect to analyzed cell lines. Targeted deletions have not yet been reported. LPA 4 (25) was the first LPA receptor with a divergent sequence that shows greater similarity to the platelet-activating factor GPCR. Comparatively less is known about this receptor. It appears to be encoded on a single exon, and both human and mouse receptors contain 370 aa with a molecular mass of ϳ42 kDa. Gene expression is most marked in the ovaries but is also observed at lower levels in several other tissues. Biological roles, null mutations, and its relationship to the other LPA receptors have not been reported.
S1P GPCRs
There are five identified S1P receptors in mammals (Tables I  and II; Figs. 2 and 3) (5, 9, 13, 26). The first receptor identified was S1P 1 (5, 8, 27, 28) , and it is also the best characterized S1P receptor. Unlike most LPA receptors it is encoded within a single exon, and this gene structure is shared by all five S1P receptors. Both human and mouse receptors contain 382 aa with an apparent molecular mass of ϳ43 kDa. As with the LPA receptors, it has wide adult tissue expression and interacts with G i proteins (Fig. 2) . It also shows responses that are related to platelet-derived growth factor signaling, because platelet-derived growth factor-induced effects are perturbed in s1p 1 (Ϫ/Ϫ) MEFs. The null genotype of s1p 1 was embryonic lethal (29) with death attributable to incomplete vascular maturation (Table II) . Conditional deletion studies demonstrate that vascular endothelial cells are the primary target for the actions of S1P 1 loss (30) (Fig. 3 ). Recent reports demonstrate specific roles for S1P 1 in lymphocyte recirculation/egress (31, 32) . S1P 2 is encoded on a single exon and contains 353 aa (human) and 352 aa (mouse) with an apparent molecular mass of ϳ39 kDa. It shows widespread tissue distribution and couples with multiple G proteins (Fig. 2) . Genetic deletion of an apparent zebra fish s1p 2 orthologue (33) revealed developmental heart defects although an analogous phenotype was not observed in independent deletions of s1p 2 in mice (34, 35) . In mice, s1p 2 (Ϫ/Ϫ) genotype demonstrated MEF signaling defects for Rho activation (Table II) . Although appearing grossly normal, some nulls revealed sporadic and at times lethal seizures in a neuroanatomically normal setting that may be related to increased excitability in neocortical pyramidal neurons (34) . By comparison, other s1p 2 (Ϫ/Ϫ) mice did not show seizure activity but did exhibit decreased litter size (35) ; the reasons for these differences may reflect background strain effects. S1P 3 is also encoded on a single exon, and both human and mouse receptors contain 378 aa residues with an apparent molecular mass of ϳ42 kDa. It shows wide tissue distribution in humans and mouse. It also couples to multiple G proteins (Fig. 2) . Gene targeting revealed no gross abnormalities aside from a slightly decreased litter size (Table II) . By contrast, MEF S1P signaling was notably affected, particularly PLC activation and Ca 2ϩ mobilization in contrast to normal Rho activation and inhibition of AC. 
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Bradycardia that is mediated by this receptor has recently been reported (Fig. 3) (31) . S1P 4 is again found encoded on a single exon. It contains 384 aa (human) and 386 aa (mouse) with an apparent molecular mass of ϳ42 kDa. It has relatively low amino acid sequence similarity to the other S1P receptors suggesting that it might prefer a distinct ligand (8) ; indeed phytosphingosine 1-phosphate (4D-hydroxysphinganine 1-phosphate) appears to be such a ligand (36) . Unlike other S1P receptors its expression pattern is predominantly in lymphoid compartments. S1P 4 couples with multiple G proteins (Fig. 2) . Targeted deletion of this receptor has not been reported. S1P 5 retains a single exon coding region (8) . It contains 398 aa (human) and 400 aa (mouse) and has an apparent molecular mass of ϳ42 kDa. It couples to multiple G proteins (Fig. 2) and shows intermediate expression levels compared with the previously mentioned receptors having notable expression in rat brain where it is expressed in white matter tracts and oligodendrocytes. In contrast to other S1P receptors it appears to inhibit mitogen-activated protein kinase activation. Genetic nulls have not yet been reported.
Agonists and Antagonists for LP GPCRs
Important tools for the study of GPCRs are appropriate agonists and antagonists (5, 37) . It is notable that many reported compounds have not been adequately validated in a range of assays or in vivo. Nevertheless, a number of promising compounds have entered the experimental literature (Table I) . Examples of LPArelated compounds (37) include Ki16425, an LPA 1 and LPA 3 antagonist (38) ; an ethanolamide derivative (VPC12249) with LPA 1 (45) . The best validated in vivo compound is the pro-drug FTY720 that shows non-selective agonism of several S1P receptors following its phosphorylation into an active species (46, 47) .
Physiological Future for GPCR-mediated LP Signaling LP signaling through GPCRs has major influences on multiple organ systems, and an increased understanding of the physiological and pathophysiological effects of LPs is perhaps the major growth area in this field (3, 5, 48, 49) . Integration of data on individual receptors into organ system biology is providing a strategic focus for the field as it necessarily diversifies into more organ-specific topic areas. Major systems influenced by LPs include both the developing and adult cardiovascular system (12, 13, 50) , reproductive system (5, 35, 51) , immune system (52-56), and nervous system (Fig. 3) (5, 8, 50 , 57-59); these represent only a partial list of influences considering the widespread expression of LP receptors viewed as a whole. Both LPA and S1P have been implicated in these influences, and the range of effects continues to increase. In addition to normal physiological processes, LP signaling has also been implicated in cancer (3, 60) , wound healing (16) , and atherosclerosis (39, 48) . Joining the effects of LPA and S1P, it is certain that other chemical forms of LPs and their cognate GPCRs will also complement the many studies noted here. Elucidating both physiological and pathophysiological roles mediated by LP GPCRs will undoubtedly fuel continued growth of this exciting field.
